A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Japanese Journal of Clinical Oncology

• Publication date

  2007-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/JJCO/HYM103PMID 17923456
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer

  2007cited by this paper
• Randomised Trial Comparing Three Different Schedules of Infusional 5FU and Raltitrexed Alone as First-Line Therapy in Metastatic Colorectal Cancer

  2006cited by this paper
• Biweekly Irinotecan and Cisplatin as Second-line Chemotherapy in Pretreated Patients with Advanced Gastric Cancer: A Multicenter Phase II Study

  2005influential reference
• Review of second-line chemotherapy for advanced gastric adenocarcinoma.

  2005cited by this paper
• Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer

  2005cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study.

  2004cited by this paper
• Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.

  2004influential reference
• Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803.

  2004influential reference
• Salvage Treatment for Advanced Gastric Cancer Using FEP (5-FU, Etoposide, Cisplatin) Combination Chemotherapy.

  2002cited by this paper
• Annual Report of the Korea Central Cancer Registry Program 2000: Based on Registered Data from 131 Hospitals.

  2002cited by this paper
• Patient survival after D1 and D2 resections for gastric cancer: long-term results of MRC randomized surgical trial

  2001cited by this paper
• Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of

  2000cited by this paper
• Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial

  1999cited by this paper
• Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer.

  1999cited by this paper
• Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer.

  1999cited by this paper
• Patient survival after D 1 and D 2 resections for gastric cancer: long-term results of the MRC randomized surgical trial

  1999cited by this paper
• Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.

  1997cited by this paper
• Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1.

  1996cited by this paper
• Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.

  1996cited by this paper
• Chemotherapy of gastric cancer.

  1996cited by this paper
• [Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group].

  1994cited by this paper
• Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials.

  1994cited by this paper
• Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group.

  1991cited by this paper
• Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin.

  1989influential reference
• Cancer of the stomach.

  1989cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper
• CHEMOTHERAPY OF GASTRIC CANCER.

  1964cited by this paper
• Cancer of the stomach.

  1951cited by this paper

• Comparison of Two Chemotherapy Regimens After First-Line Treatment for HER2-Negative Metastatic Gastric Cancer

  2023cites this paper
• A case of effective disease control of advanced gastric cancer following ramucirumab plus FOLFIRI in second line treatment in clinical practice

  2020cites this paper
• Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers

  2018cites this paper
• Chronic myelomonocytic leukemia presenting as upper limb gangrene

  2018cites this paper
• 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane.

  2017cites this paper
• Third-line systemic treatment versus best supportive care for advanced/metastatic gastric cancer: A systematic review and meta-analysis.

  2017cites this paper
• Metastatic gastric cancer treatment: Second line and beyond.

  2016cites this paper
• Three Weekly Irinotecan and Bolus 5-Fluorouracil Combination in the First Line Treatment of Advanced Gastric Cancer - A Single Institution Experience

  2016cites this paper
• Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program

  2016cites this paper
• Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies

  2015cites this paper
• Second-Line Treatment of Advanced Gastric Cancer: Where Do We Stand?

  2015cites this paper
• FOLFIRI regimen as second-line treatment of metastatic gastric cancer: a retrospective analysis of efficacy, safety and prognostic factors

  2015cites this paper
• Gastric cancer: past accomplishments, present approaches and future aspirations

  2013cites this paper
• Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer

  2013cites this paper
• Geographic differences in approach to advanced gastric cancer: Is there a standard approach?

  2013cites this paper
• Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival

  2013influential citation
• Irinotecan, leucovorin and 5-fluorouracil (modified FOLFIRI) as salvage chemotherapy for frail or elderly patients with advanced gastric cancer.

  2012influential citation
• Second-line chemotherapy for advanced gastric cancer in Korea

  2012cites this paper
• The Role of Chemotherapy in Metastatic Disease

  2012cites this paper
• The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens

  2012cites this paper
• Advanced Gastroesophageal Carcinoma: An Update on the Current Therapeutic Landscape

  2012cites this paper
• Evaluation of efficacy and safety of FOLFIRI for elderly patients with gastric cancer: a first-line phase II study.

  2011cites this paper
• Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: Lessons from clinical practice

  2011cites this paper
• Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer

  2011cites this paper
• The role of chemotherapy in metastatic gastric cancer.

  2011cites this paper
• Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer

  2011influential citation
• Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: lessons from clinical practice.

  2011cites this paper
• A Phase II Trial of 5-Fluorouracil, Leucovorin and Mitomycin C in Patients with Advanced Gastric Cancer

  2011cites this paper
• Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease.

  2010cites this paper
• [Metastatic gastric cancer successfully treated with surgery and chemotherapy. Case report].

  2010cites this paper
• Advanced gastric cancer--slow but steady progress.

  2010cites this paper
• A Phase II Study of Irinotecan, Continuous 5-Fluorouracil, and Leucovorin (FOLFIRI) Combination Chemotherapy for Patients With Recurrent or Metastatic Gastric Cancer Previously Treated With a Fluoropyrimidine-Based Regimen

  2010cites this paper
• Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis

  2009cites this paper
• A pilot study of irinotecan combined with 5-fluorouracil and leucovorin for the treatment of Chinese patients with locally advanced and metastatic gastric cancer.

  2009cites this paper
• A Phase II Study of Irinotecan With Biweekly, Low Dose Leucovorin and Bolus and Continuous Infusion 5-Fluorouracil (Modified FOLFIRI) as First Line Therapy For Patients With Recurrent or Metastatic Gastric Cancer

  2009cites this paper
• Is there a role for second-line chemotherapy in advanced gastric cancer?

  2009cites this paper
• Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer

  2009cites this paper
• Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI.

  2009cites this paper
• Short-term efficacy of Cetuximab-contained regimen on patients with advanced gastrointestinal (noncolorectal) cancer: Experiences of 16 patients in single institute

  2009cites this paper
• A Pilot Study of Irinotecan Combined with 5-Fluorouracil and Leucovorin for the Treatment of Chinese Patients with Locally Advanced and Metastatic Gastric Cancer

  2009cites this paper
• Cost-effectiveness analysis of chemotherapy for advanced gastric cancer in China.

  2008cites this paper
• Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer.

  2008cites this paper